doi: /j.ijrobp
|
|
- Asher Walters
- 5 years ago
- Views:
Transcription
1 doi: /j.ijrobp Int. J. Radiation Oncology Biol. Phys., Vol. 79, No. 4, pp , 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved /$ see front matter ASTRO GUIDELINE LIMITATIONS OF THE AMERICAN SOCIETY OF THERAPEUTIC RADIOLOGY AND ONCOLOGY CONSENSUS PANEL GUIDELINES ON THE USE OF ACCELERATED PARTIAL BREAST IRRADIATION FRANK VICINI, M.D.,* DOUGLAS ARTHUR, M.D., y DAVID WAZER, M.D., z PETER CHEN, M.D.,* CHRISTINA MITCHELL, R.N.,* MICHELLE WALLACE, R.N.,* LARRY KESTIN, M.D.,* AND HONG YE, M.S.* *Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI; y Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA; and z Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA Purpose: We applied the American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus Panel (CP) guidelines for the use of accelerated partial breast irradiation (APBI) to treated with this technique to determine the ability of the guidelines to differentiate with significantly different clinical outcomes. Methods and Materials: A total of 199 treated with APBI and 199 with whole-breast irradiation (WBI) (matched for tumor size, nodal status, age, margins, receptor status, and tamoxifen use) were stratified into the three ASTRO CP levels of suitability ( suitable, cautionary, and unsuitable ) to assess rates of ipsilateral breast tumor recurrence (IBTR), regional nodal failure, distant metastases, disease-free survival, cause-specific survival, and overall survival based on CP category. Median follow-up was 11.1 years. Results: Analysis of the APBI and WBI patient groups, either separately or together (n = 398), did not demonstrate statistically significant differences in 10-year actuarial rates of IBTR when stratified by the three ASTRO groups. Regional nodal failure and distant metastasis were generally progressively worse when comparing the suitable to cautionary to unsuitable CP groups. However, when analyzing multiple clinical, pathologic, or treatment-related variables, only patient age was associated with IBTR using WBI (p = 0.002). Conclusions: The ASTRO CP suitable group predicted for a low risk of IBTR; however, the cautionary and unsuitable groups had an equally low risk of IBTR, supporting the need for continued refinement of patient selection criteria as additional outcome data become available and for the continued accrual of to Phase III trials. Ó 2011 Elsevier Inc. Breast-conserving therapy, Brachytherapy, Radiation, Partial breast irradiation, Breast cancer. INTRODUCTION Over the past decade, there has been increased interest in the use of accelerated partial breast irradiation (APBI) as an alternative to whole breast irradiation (WBI) for adjuvant radiation treatment after breast-conserving surgery. Accelerated partial breast irradiation offers decreased overall treatment times and a potential decrease in the radiation dose delivered to nontarget portions of the breast and adjacent tissues. However, there are several possible disadvantages to APBI. One primary concern is that occult foci of cancer in remote areas of the breast (away from the tumor bed) may remain untreated. Given the tremendous interest in APBI, numerous multicenter, prospective randomized clinical trials (including the NSABP B39/RTOG 0413 Phase III trial) have been initiated or completed to compare the effectiveness and safety of APBI vs. WBI (1 3). Despite limited long-term clinical data, the use of APBI outside of clinical trials has increased sharply. In the past, few data were available to help guide physicians as to which could be safely treated with APBI and which should more appropriately receive WBI. In light of increasing evidence that postoperative adjuvant radiation therapy significantly improves long-term overall survival after breastconserving surgery (4), it seems prudent that conservative patient selection criteria for APBI should be followed until additional long-term data are available to indicate otherwise. Unfortunately, the optimal set of selection criteria to use when applying APBI remains poorly defined. Given these concerns, the American Society of Therapeutic Radiology and Oncology (ASTRO) Health Services Research Committee convened a Task Force of breast cancer experts from various oncologic specialties to develop Reprint requests to: Frank A. Vicini, M.D., FACR, Department of Radiation Oncology, Beaumont Cancer Institute, William Beaumont Hospital, 3601 W. 13 Mile Road, Royal Oak, MI Tel: (248) ; Fax: (248) ; fvicini@ beaumont.edu 977 Conflict of interest: none. Received Nov 3, 2009, and in revised form Dec 15, Accepted for publication Dec 15, 2009.
2 978 I. J. Radiation Oncology d Biology d Physics Volume 79, Number 4, 2011 a consensus statement addressing patient selection criteria and best practices for the application of APBI outside of clinical trials (2). These recently published recommendations were based on the results of a systematic literature review of the limited APBI data and were also supplemented by the expert opinions of the Task Force members using data applying WBI to treat. Because knowledge regarding APBI is rapidly accumulating, the Task Force acknowledged that the consensus statement would require frequent updates and modifications to account for ongoing research findings. It was hoped that the recommendations contained within the consensus statement would help to provide guidance not only for the use of APBI outside of a clinical trial but also to serve as a framework to promote additional clinical investigations into the optimal role of APBI in the treatment of breast cancer. To that end, we applied the ASTRO Consensus Panel (CP) guidelines for the application of APBI to a large group of treated at our institution with this technique to help clarify their ability to differentiate with significantly different clinical outcomes. Whole-breast irradiation To compare the rate of IBTR in a comparable group of treated with WBI, each APBI patient was matched with one WBI patient at WBH. The patient database at WBH extends from 1980 through 1997 and consists of 1,503 consecutively treated with WBI (all treatment data were collected retrospectively). Each WBI patient underwent lumpectomy and axillary lymph node dissection followed by standard WBI at a median total dose to the tumor bed of 60 Gy. Of these WBI therapy, 709 (47%) were initially selected according to the following APBI protocol selection criteria: infiltrating ductal histology, absence of an extensive intraductal component, negative margins, tumor size <3.0 cm, performance of an axillary lymph-node dissection, and three or fewer involved lymph nodes. Each APBI patient was randomly matched to a unique patient from among the 709 WBI therapy who met the following additional matching criteria. Patients were matched one-to-one according to age (10 years), tumor size (5 mm), nodal status (negative vs. one to three positive nodes), estrogen receptor status (positive vs. negative vs. unknown), and the use of adjuvant tamoxifen therapy (yes vs. no). Outcome (i.e., any type of tumor recurrence) was blinded for both the WBI and APBI when matching was performed. METHODS AND MATERIALS Study participants The study population consists of 199 treated with APBI and 199 treated with WBI. All (see below) were categorized according to the ASTRO CP guidelines for APBI and analyzed for the ability of these groupings to predict differences in clinical outcome compared with traditional clinical, pathologic, and treatment-related variables. APBI A total of 199 consecutive with invasive early-stage breast cancer were prospectively treated at William Beaumont Hospital (WBH) with APBI using interstitial brachytherapy directed only at the region of the tumor bed as part of their BCT from 1993 to All eligible had Stage I/II breast cancer. Eligibility criteria have been published in previous experiences and have included infiltrating ductal carcinomas less than 3.0 cm in diameter, negative surgical margins ($2 mm), more than 40 years of age at diagnosis, and negative lymph node status (5). Patients with an extensive intraductal component, infiltrating lobular histology, ductal carcinoma in situ, and clinically significant areas of lobular carcinoma in situ were generally excluded (6). Patients who did not meet all of these eligibility criteria for APBI were also included in this analysis. Several of these had more than one criterion that did not meet all eligibility criteria (i.e., positive lymph nodes). Follow-up was complete through September 2008 for the APBI. All were treated with radiation techniques according to the guidelines of one of three different protocols for APBI brachytherapy (5). A total of 120 (60%) were treated as in with a low-dose-rate (LDR) implant, and 79 (40%) were treated as out with a high-dose-rate (HDR) implant. A total of 139 (70%) received adjuvant therapy after completion of APBI radiation therapy: 25 (13%) received adjuvant systemic chemotherapy, and 114 (57%) received adjuvant tamoxifen therapy. ASTRO CP groups All (APBI and WBI) were categorized into one of three ASTRO CP groups (outlined in two recent publications) as described below. Suitable. Patients were required to have all the following characteristics: age $60 years, BRCA1/2 mutation absent, tumor size #2 cm, stage T1, margins negative by at least 2 mm, any grade, no lymphatic vessel invasion (LVI), ER status was positive, tumors must be unicentric only and clinically unifocal with total size #2.0 cm, only invasive ductal histology or other favorable subtypes, pure DCIS was not allowed, EIC not allowed, associated LCIS allowed, stage pn0 (i-, i+), sentinel biopsy or axillary lymph node dissection required, and neoadjuvant therapy not allowed. Cautionary. Patients were classified as of cautionary status if they had any one or more of the following characteristics: age 50 to 59 years, tumor size 2.1 to 3.0 cm, stage T0 or T2, margins close (<2 mm), LVSI limited/focal, ER status negative, clinically unifocal with total size 2.1 to 3.0 cm, invasive lobular, pure DCIS #3 cm, EIC #3 cm. Unsuitable. Patients in this group had any one or more of the following: age <50 years, BRCA1/2 mutation present, tumor size >3 cm, Stage T3 to T4, margins positive, LVSI extensive, multicentricity present, microscopically multifocal >3 cm in total size or if clinically multifocal, pure DCIS >3 cm in size, EIC >3 cm in size, Stage pn1, pn2, pn3 nodal surgery not performed, or neoadjuvant therapy used. Outcome measures An IBTR was defined as the recurrence of cancer in the treated breast before or at the time of regional failure or metastases. Contralateral breast failure was defined as the development of breast cancer in the opposite, untreated breast. Overall survival (OS) was defined as all deaths from any cause. Cause-specific survival (CSS) was defined as all deaths attributed only to breast cancer. Disease-free survival (DFS) was defined as all events attributed to breast cancer, i.e., local, regional, or distant recurrence.
3 Limitations of ASTRO Consensus Panel guidelines on APBI d F. VICINI et al. 979 ASTRO grouping Table 1. Study population vs. ASTRO guideline group All (n = 398) APBI (n = 199) Statistical analysis The estimated likelihood of events for IBTR, contralateral breast failure, DFS, OS, and CSS were calculated by the Kaplan-Meier method, and the statistical significance of differences between treatment and CP groups were calculated using the log-rank test. The association of categorical variables (e.g., margin status) with treatment group was analyzed using Fisher s two-tailed exact test. The statistically significant differences between two sample means for continuous variables (e.g., patient age in years) were analyzed using the Student s unpaired t-test. Regression analysis was performed using the Cox proportional hazards model. All time intervals were calculated from the date of completion of RT. A p value of #0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL), and all statistical tests were two-sided. RESULTS EBRT matched (n = 199) N (%) N (%) N (%) p Value Suitable 176 (44.2%) 95 (47.7%) 81 (40.7%) Cautionary 143 (35.9%) 63 (31.7%) 80 (40.2%) Unsuitable 79 (19.8%) 41 (20.6%) 38 (19.1%) Abbreviations: APBI = accelerated partial breast irradiation; AS- TRO = American Society of Therapeutic Radiology and Oncology; EBRT = external beam radiation therapy. The median follow-up was 11.1 years for all (9.33 years for APBI and for WBI, p < 0.001). The median age at diagnosis was years for all (65.0 years for APBI and for WBI, p = 0.10) Patients were categorized according to the three ASTRO CP groups in Tables 1 to 7. There were no statistically significant differences in the number of in each ASTRO grouping based on treatment technique (Table 1). Suitable For APBI, 47.7% of had all of the suitable ( S ) characteristics and for WBI, 40.7% had all of these findings (p = 0.197). Cautionary For APBI, 31.7% of had one or more of the cautionary ( C ) characteristics and for WBI, 40.2% had these findings. For APBI, the distribution of characteristics that placed them into this CP group was as follows: age 50 to 59 years (n = 36), tumor size 2.1 to 3 cm (n = 10), negative estrogen receptor status (n = 19), margins negative but <2 mm (n = 4), presence of an EIC but <3 cm (n = 8), and pure DCIS <3 cm or lobular histology (n = 1). Some had more than one of these findings. For WBI, the distribution of characteristics that placed them into this CP group was as follows: age 50 to Table 2. Ten-year outcome for all (n = 398) vs. ASTRO group Suitable Cautionary Unsuitable p Value Local recurrence 3.3% 3.9% 5.5% Regional nodal 0% 0.7% 4.0% 0.017* Failure Distant metastases 3.7% 7.6% 12.1% Disease-free 93.1% 89.3% 85.2% Survival Overall survival 75.9% 81.7% 83.0% 0.011* Cause-specific Survival 96.5% 93.6% 90.9% Abbreviation: ASTRO = American Society of Therapeutic Radiology and Oncology. * p < years (n = 38), tumor size 2.1 to 3 cm (n = 12), negative estrogen receptor status (n = 21), margins negative but <2 mm (n = 0), presence of an EIC but < 3 cm (n = 22), and pure DCIS <3 cm or lobular histology (n = 6). Some had more than one of these findings. Unsuitable For APBI, 20.6% of had any of the unsuitable ( U ) characteristics, and for WBI, 19.1% had any of these findings. For APBI, the distribution of characteristics that placed them into this CP group was as follows: age <50 years (n = 19), tumor size >3 cm (n = 0), positive margins (n = 1), positive lymph nodes (n = 23), and DCIS >3 cm (n = 0). Some had more than one of these findings. For WBI, the distribution of characteristics that placed them into this CP group was as follows: age <50 years (n = 15), tumor size >3 cm (n = 1), positive margins (n = 1), positive lymph nodes (n = 23), and DCIS >3 cm (n = 0). Some had more than one of these findings. Tables 2 to 4 present the 10-year actuarial rates of various clinical endpoints for all (n = 398), APBI only (n = 199), and WBI only (n = 199) vs. the three ASTRO groupings. In APBI (Table 3), use of Table 3. Ten-year outcome for APBI (n = 199) vs. ASTRO group Suitable (n = 95) Cautionary (n = 63) Unsuitable (n = 41) p Value Local recurrence 2.6% 7.8% 2.5% Regional nodal 0% 1.7% 5.9% failure Distant metastases 0% 7.1% 11.2% 0.018* Disease-free 97.4% 85.3% 88.9% survival Overall survival 73.6% 74.3% 82.1% Cause-specific Survival 98.3% 91.4% 92.2% Abbreviations: APBI = accelerated partial breast irradiation, AS- TRO = American Society of Therapeutic Radiology and Oncology. * p < 0.05.
4 980 I. J. Radiation Oncology d Biology d Physics Volume 79, Number 4, 2011 Table 4. Ten-year outcome for WBI (n = 199) vs. ASTRO group Suitable (n = 81) Cautionary (n = 79) Unsuitable (n = 39) p Value Local recurrence 4.1% 1.2% 8.4% Regional nodal failure 0% 0% 2.7% Distant metastases 7.7% 8.0% 13.2% Disease-free survival 88.4% 92.1% 81.5% Overall survival 78.8% 86.2% 84.2% Cause-specific survival 94.6% 94.6% 89.5% Abbreviations: ASTRO = American Society of Therapeutic Radiology and Oncology; WBI = whole breast irradiation. Table 6. Risk of 10-year regional nodal failure vs. ASTRO group and treatment ASTRO grouping All (n = 398) APBI (n = 199) EBRT matched (n = 199) p Value Suitable (n = 176) 0% 0% 0% N/A Cautionary (n = 132) 0.7% 1.7% 0% Unsuitable (n = 90) 4.0% 5.9% 2.7% p Value 0.017* Abbbreviations: APBI = Accelerated partial breast irradiation; ASTRO = American Society of Therapeutic Radiology and Oncology, EBRT = External beam radiation therapy; N/A = not available. * p < the CP groupings resulted in statistically significant differences in the rate of DM (p = 0.018). Table 5 presents the 10-year actuarial rates of IBTR vs. ASTRO groups and treatment technique. There were no statistically significant differences in the IBTR rate regardless of CP group or treatment technique. Table 6 presents the 10-year actuarial rates of RNF vs. AS- TRO groups and treatment technique. There were no statistically significant differences in RNF rates regardless of CP group or treatment technique Table 7 presents the 10-year actuarial rates of DMs vs. AS- TRO groups and treatment technique. As noted above, application of the CP groupings resulted in statistically significant differences in the rate of DM (p = 0.018) only in APBI. Table 8 presents a univariate analysis of variables associated with IBTR in all combined and in APBI or WBI separately. In WBI, only age at diagnosis (both as a categorical variable, p = 0.007, and as a continuous variable, p = 0.002) was associated with IBTR. The ASTRO CP groupings were not associated with IBTR in treated with APBI. Table 9 presents a univariate analysis of variables associated with RNF or DM for all (n = 398) and RNF for APBI alone (n = 199). On multivariate analysis (data not shown), only the presence of an EIC was associated with RNF in all (p = 0.018) and in APBI (p = 0.028). The ASTRO CP groupings were not associated with any endpoint (RNF or DM) for either group of (WBI or APBI). Table 5. Risk of 10-year local recurrence vs. ASTRO group and treatment type ASTRO grouping All (n = 398) APBI (n = 199) EBRT matched (n = 199) p Value Suitable (n = 176) 3.3% 2.6% 4.1% Cautionary (n = 132) 3.9% 7.8% 1.2% Unsuitable (n = 90) 5.5% 2.5% 8.4% p Value Abbreviations: APBI = accelerated partial breast irradiation; AS- TRO = American Society of Therapeutic Radiology and Oncology; EBRT = external beam radiation therapy. DISCUSSION We applied the ASTRO CP guidelines for the use of APBI to treated with this technique at William Beaumont Hospital to evaluate the predictive ability of the described levels of suitability in regard to significant differences in long-term clinical outcome and appropriateness for treatment with APBI. With a median follow-up of 11.1 years, analysis of both APBI and a matched group of WBI (either together or by method of treatment alone) when stratified by the three ASTRO CP groups did not demonstrate statistically significant differences in the 10-year actuarial rates of IBTR. Regional nodal failure and DM were generally progressively worse when comparing the S to C to U groups. However, when analyzing multiple variables potentially associated with IBTR, only age at diagnosis was associated with IBTR when using WBI (p = 0.002). The ASTRO CP groupings did not independently differentiate who may or may not be more appropriately treated with this technique. These results await validation from other large APBI databases and suggest that further refinement of these groupings may be needed. They also support the continued enrollment of high-risk considered for APBI in Phase III clinical trials. Overview Despite limited long-term data available on the use of APBI, treatment outside of clinical trials has increased Table 7. Risk of 10-year distant metastases vs. ASTRO group and treatment type ASTRO grouping All APBI EBRT matched subjects (n = 398) (n = 199) (n = 199) p Value Suitable (n = 176) 3.7% 0% 7.7% 0.006* Cautionary (n = 132) 7.6% 7.1% 8.0% Unsuitable (n = 90) 12.1% 11.2% 13.2% p Value * Abbreviations: APBI = accelerated partial breast irradiation; AS- TRO = American Society of Therapeutic Radiology and Oncology; EBRT = external beam radiation therapy. * p < 0.05.
5 Limitations of ASTRO Consensus Panel guidelines on APBI d F. VICINI et al. 981 Table 8. Univariate analysis of variables associated with local recurrence All (n = 398) WBI (n = 199) APBI (n = 199 Variable* OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value Age <50 vs. $ ( ) ( ) ( ) continuous ( ) ( ) ( ) Tumor stage T1 vs. T ( ) ( ) Tumor size (mm) #20 vs. > ( ) ( ) ( ) Histology ductal vs. lobular EIC absent vs. present ( ) ( ) ( ) Grade I/II vs. III ( ) ( ) ( ) ER status ( ) vs. (+) ( ) ( ) ( ) Margins #2 vs. >2 mm ( ) Nodal status (+) vs. ( ) ( ) ( ) ( ) Treatment WBI vs. APBI ( ) NA NA NA NA ASTRO grouping I/II vs. III ( ) ( ) ( ) I vs. II/III ( ) ( ) ( ) Abbreviations: APBI = accelerated partial breast irradiation; ASTRO = American Society of Therapeutic Radiology and Oncology; ASTRO grouping: I = suitable; II = cautionary; III = unsuitable; CI = confidence interval; ER = estrogen receptor; EIC = extensive intraductal component; LVI = lymphatic vessel invasion; OR = odds ratio (comparing the reference group). * First group is reference group for the following variables. markedly (1). For example, it is estimated that more than 45,000 women in the United States have been treated with the MammoSite (Hologic, Bedford, MA) breast brachytherapy catheter alone to deliver APBI. This does not include the thousands of other women treated with external beam APBI techniques, intraoperative, single fraction radiation (both in the United States and Europe) or other newer forms (devices) of APBI currently being used in clinic practice (7 9). Combined with increasing evidence that postlumpectomy RT improves long-term overall survival, most breast cancer experts agree that conservative patient selection criteria for APBI should be developed and followed until additional data from Phase III trials are available. Given these concerns, the ASTRO Health Services Research Committee convened a Task Force of breast cancer experts to generate a consensus statement regarding optimal patient selection criteria and best practices for the application of APBI. These recommendations were based on the results of a systematic literature review of APBI data and were supplemented by the expert opinions of the Task Force members. A remarkable achievement of the Task Force was that after a comprehensive literature review, a broad-based consensus was achieved to definitively identify that can be appropriately treated with APBI outside the context of a clinical trial. However, the Task Force also readily acknowledged that there were insufficient data to determine which were clearly inappropriate for APBI. This critical absence of data drove the Task Force to rely heavily upon expert opinion in formulation of the guideline categories of cautionary and unsuitable as applied to APBI that is offered outside the confines of a clinical trial. In retrospect, the specific word choice in labeling these categories may have been misleading, as it did not fully reflect the scope of contemporary data for APBI. As the current study clearly indicates, characterized as cautionary and unsuitable are, in fact, appropriate for APBI provided that it is in the context of ongoing structured clinical investigation. The ASTRO Task Force explicitly recognized the need for continued data accumulation for in the cautionary and unsuitable categories and fully anticipated that the current guidelines would require periodic update and modification. Development of the ASTRO Consensus Panel Guideline criteria Developing selection criteria for the optimal use of APBI requires the identification of subsets of with a very low risk of clinically occult disease remote from the lumpectomy cavity. Unfortunately, few data have been conclusively identified from pathologic studies or prospective clinical
6 982 I. J. Radiation Oncology d Biology d Physics Volume 79, Number 4, 2011 Table 9. Univariate analysis of variables associated with regional nodal failure or distant metastases in all (n = 398) and APBI (n = 199) Regional nodal failure (n = 398) Distant metastases (n = 398) APBI only, regional nodal failure Variable* OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value Age <50 vs. $ ( ) ( ) continuous ( ) ( ) ( ) Tumor stage T1 vs. T ( ) ( ) ( ) Tumor size (mm) #20 vs. > ( ) ( ) ( ) Histology ductal vs. lobular EIC Absent vs. present ( ) ( ) ( ) Grade I/II vs. III ( ) ER status ( ) vs. (+) ( ) ( ) ( ) Margins #2 vs. >2 mm ( ) Nodal status (+) vs. ( ) ( ) ( ) ( ) Treatment WBI vs. APBI ( ) ( ) NA NA ASTRO grouping I/II vs. III ( ) ( ) I vs. II/III ( ) Abbreviations: APBI = accelerated partial breast irradiation; ASTRO grouping: I = suitable, II = cautionary, III = unsuitable; CI = confidence interval; ER = estrogen receptor; EIC = extensive intraductal component; LVI = lymphatic vessel invasion; NA = not applicable; OR = odds ratio (comparing the reference group). * First group is reference group for the following variables. studies of APBI to clearly define this subgroup of breast cancer (10). As a result, the proposed clinical pathologic selection criteria for the ASTRO suitable group were developed (according to the CP authors) based entirely upon the common inclusion criteria and characteristics of enrolled in prospective single-arm studies of APBI that had a minimum of 4 years follow-up and that reported a low risk of IBTR (11). These data were then supplemented by the Task Force s general knowledge of risk factors for IBTR with WBI. It was acknowledged by the authors that there may be other groups of for whom APBI will prove to be suitable, but the Task Force believed that there was insufficient evidence to identify them at the time of CP publication. The ASTRO cautionary group included those for whom the Task Force expressed uncertainty regarding the appropriateness of APBI, although they acknowledged at least some in this group had been included in single-arm, prospective trials. Again, there were no APBI data available that demonstrated (or even suggested) in this cautionary group had significantly different (worse) rates of IBTR, RNF or DM when applying APBI. Finally, the unsuitable group included those for whom there was very limited evidence (too few treated with these characteristics) from clinical trials to support the use of APBI. Furthermore, the Task Force strongly suggested that those who remain eligible for the ongoing RTOG 0413/ NSABP B-39 randomized clinical trial ( aged <50 years or any age with estrogen receptor [ER] negative tumors or any age with pn1 tumors) should be strongly encouraged to participate in this important trial. It should be noted again that this category was not developed because of negative data on the application of APBI in this patient group. In fact, there have been several small, recently published studies in these higher-risk that have demonstrated acceptable rates of IBTR, further supporting the ethical and appropriate randomization of these on the NSABP B39/RTOG 0413 phase III trial so that the breadth of APBI application can be correctly defined (12, 13). Several other societies and organizations have also provided guidelines for the application of APBI both on and off-protocol. These include statements by the American Brachytherapy Society (ABS) (11, 14), the American Society of Breast Surgeons (ASBrS) (15), the American College of Radiation Oncology (ACRO), and a consensus statement from three German oncology societies (the German Society of Radiation Oncology, the German Society of Senology, and the Working Group for Gynecological Oncology of the German Cancer Society) (16). Many of the selection criteria from these other societies overlap with those of the ASTRO CP guidelines; but, generally, the methodology used to formulate
7 Limitations of ASTRO Consensus Panel guidelines on APBI d F. VICINI et al. 983 these recommendations is similar. Typically, all of these groups (1) support the participation of in randomized clinical studies comparing APBI with WBRT, (2) discourage the routine use of APBI outside clinical trials for higher risk, and (3) suggest that until definite results show that APBI neither impairs therapeutic outcome nor cosmetic results, WBI should remain the gold standard in the treatment of early breast cancer. This analysis did demonstrate that the CP suitable group could be used as a tool to help select appropriate for the application of APBI on or off protocol, yet failed to verify that the cautionary and unsuitable groups identify experiencing a higher rate of IBTR or are inappropriate for APBI. These findings need to be viewed cautiously, however. This was a relatively small group of treated with only one form of APBI (at a single institution). In addition, the number of events (IBTRs) was low, thus limiting the statistical power to validate any associations. Clearly, additional studies using other forms of APBI are needed to determine what refinements in these groupings may be needed. It may also be possible that other variables need to be explored as potential risk factors for the development of an IBTR when applying APBI. These as-yet-unidentified risk factors may or may not be similar to those observed with conventional WBI. Current analysis Only a few other groups have published their experience on potential risk factors for the development of an IBTR with the application of APBI. Most APBI studies have too few treated, a relatively short follow-up period, and a limited number of IBTR events. However, in a series of 80 treated with the MammoSite breast brachytherapy catheter to deliver APBI, Chao et al. identified young age as a potential risk for the development of an IBTR (17). More recently, Vicini et al. analyzed 1,449 cases also treated with the MammoSite to deliver APBI on the ASBrS MammoSite registry trial. With a median follow-up of 53 months, they found that estrogen receptor negative tumors (p = ) were associated with IBTR at 5 years in with invasive breast cancer and young age (p = ) and margin staus (p = ) in with DCIS. It is hoped that additional data such as these will become available from larger series of treated with APBI to help clarify these important associations. Until then, conservative selection criteria should be applied in identifying to be treated off-protocol while higher-risk (classified by the CP guidleines as unsuitable) should continue to be directed toward enrollment in phase III trials such as the NSABP B39/RTOG 0413 study. CONCLUSION The ASTRO CP guidelines for the use of APBI, when applied to a large database of treated with APBI, identified a select group of who are appropriately treated with APBI experiencing low rates of IBTR, but the guidelines were unable to independently differentiate cases that may be more appropriately treated with WBI. These results await validation from other large APBI databases and suggest that further refinements of these ASTRO CP groupings may be needed. These findings also support the continued enrollment of high-risk treated with APBI in Phase III clinical trials and emphasize the importance of the completion of these trials so that, in the future, treatment decisions can be made on existing outcome data. REFERENCES 1. Swanson TA, Vicini FA. Overview of accelerated partial breast irradiation. Curr Oncol Rep 2008;10: Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg 2009; 209: Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009;74: Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366: Antonucci JV, Wallace M, Goldstein NS, et al. Differences in patterns of failure in treated with accelerated partial breast irradiation vs. whole-breast irradiation: A matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys 2009;74: Vicini FA, Kestin L, Chen P, et al. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst 2003;95: Vicini FA, Chen P, Wallace M, et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2007;69: Brown S, McLaughlin M, Pope K, et al. Initial radiation experience evaluating early tolerance and toxicities in undergoing accelerated partial breast irradiation using the Contura Multi-Lumen Balloon breast brachytherapy catheter. Brachytherapy 2009;8: Veronesi U, Orecchia R, Luini A, et al. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: Experience with 590 cases. Ann Surg 2005;242: Vicini FA, Kestin LL, Goldstein NS. Defining the clinical target volume for with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: A pathologic analysis. Int J Radiat Oncol Biol Phys 2004;60: Arthur DW, Vicini FA, Kuske RR, et al. Accelerated partial breast irradiation: An updated report from the American Brachytherapy Society. Brachytherapy 2003;2: Patel RR, Christensen ME, Hodge CW, et al. Clinical outcome analysis in high-risk vs. low-risk eligible for national surgical adjuvant breast and bowel B-39/radiation therapy oncology group 0413 trial: Five-year results. Int J Radiat Oncol Biol Phys 2008;70:
8 984 I. J. Radiation Oncology d Biology d Physics Volume 79, Number 4, Khan AJ, Vicini F, Beitsch P, et al. Local control, toxicity, andcosmesisinwomenyoungerthan50enrolledontothe American Society of Breast Surgeons MammoSite Radiation Therapy System registry trial. Ann Surg Oncol 2009;16: Arthur D, Vicini F, Kuske RR, et al. Accelerated partial breast irradiation: An updated report from the American Brachytherapy Society. Brachytherapy 2002;1: Jeruss JS, Vicini FA, Beitsch PD, et al. Initial outcomes for treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann Surg Oncol 2006;13: Sauer R, Sautter-Bihl ML, Budach W, et al. Accelerated partial breast irradiation: Consensus statement of 3 German oncology societies. Cancer 2007;110: Chao KK, Vicini FA, Wallace M, et al. Analysis of treatment efficacy, cosmesis, and toxicity Using the MammoSite Breast Brachytherapy Catheter to deliver accelerated partial-breast irradiation: The William Beaumont Hospital Experience. Int J Radiat Oncol Biol Phys 2007;69:32 40.
Current Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationBreast Conservation Therapy
May 18, 2018 Breast Conservation Therapy One Treatment No Longer Fits All Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. Define stages of breast cancer that are candidates
More informationTrends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States
Trends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY
More informationObjectives Intraoperative Radiation Therapy for Early Stage Breast Cancer
Objectives Intraoperative Radiation Therapy for Early Stage Breast Cancer Cristina Lopez-Peñalver, MD, FACS October 11, 2014 Disclosures I have no relevant commercial relationships to disclose. Discuss
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
doi:10.1016/j.ijrobp.2007.02.026 Int. J. Radiation Oncology Biol. Phys., Vol. 69, No. 1, pp. 32 40, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front matter
More informationClinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
More informationClinical Investigation: Breast Cancer
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Breast Cancer How Do the ASTRO Consensus Statement Guidelines for the Application of Accelerated Partial
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
- Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER
ACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER KHANH NGUYEN, MD, MA DEPARTMENT OF RADIATION ONCOLOGY BAYHEALTH CANCER CENTER BREAST CANCER STATISTICS Most common
More informationIntraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationAccelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation OSCO/OU Stephenson Cancer Center Saturday, March 5, 2016 Robert Kuske, MD, FAACE Founder, Medical Director Arizona Breast Cancer Specialists Scottsdale, Arizona 1
More informationAccelerated Partial Breast Irradiation (APBI)
Accelerated Partial Breast Irradiation (APBI) Michael Zhang (MSIV), Matthew Spraker, MD, PhD (PGY3) Faculty Mentor: Janice Kim, MD University of Washington/Seattle Cancer Care Alliance Seattle, WA Case
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2012 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2013 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationAccelerated Partial Breast Irradiation and Hypofractionated Whole Breast Radiation
Accelerated Partial Breast Irradiation and Hypofractionated Whole Breast Radiation Bryan P Rowe, MD 1 and Meena S Moran, MD 2 1. Resident; 2. Associate Professor, Department of Therapeutic Radiology, Yale
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationHypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
More informationEvaluation of three APBI techniques under NSABP B-39 guidelines
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 11, NUMBER 1, WINTER 2010 Evaluation of three APBI techniques under NSABP B-39 guidelines Daniel Scanderbeg, a Catheryn Yashar, Greg White, Roger Rice,
More informationAdvances in Breast Cancer
Advances in Breast Cancer Developed in collaboration Learning Objectives Upon completion, participants should be able to: Apply genomic medicine to treatment decisions for patients with HR+/HER2- early
More informationCorporate Medical Policy
Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy
More informationAccelerated Partial Breast Irradiation: Potential Roles Following Breast-Conserving Surgery
APBI is a promising technique in selected patients with early-stage breast cancer, but further study is needed on outcome and toxicity associated with this approach. Nick Patten. Passing Light (detail).
More informationBrachytherapy: The precise answer for tackling breast cancer. Because life is for living
Brachytherapy: The precise answer for tackling breast cancer Because life is for living Table of contents Executive summary 3 Introduction 4 Management of early stage breast cancer 5 Radiotherapy options
More informationEARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT
May 13, 2016 EARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. List treatment options for early stage breast cancer. 2.
More informationAccelerated partial breast irradiation: state of the art
Accelerated partial breast irradiation: state of the art P.A. Coucke, N. Jansen, L. Jánváry, C. Louis, J. Vanderick, A. Rorive, J. Collignon, E. Lifrange, S. Maweja, G. Jerusalem Accelerated partial breast
More informationIORT What We ve Learned So Far
IORT What We ve Learned So Far The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationPartial Breast Irradiation for Breast Conserving Therapy
To Radiate or Not? Is APBI the Right Compromise Solution? Partial Breast Irradiation for Breast Conserving Therapy Julia White MD Professor, Radiation Oncology Agenda Role of radiotherapy in breast conservation
More informationPatient Selection for APBI. C. Polgár National Institute ofoncology, Budapest, Hungary
Patient Selection for APBI C. Polgár National Institute ofoncology, Budapest, Hungary Patient-, tumour- and treatment related factors affecting decision making in patient selection for APBI Patient age
More informationSlide 1. Slide 2. Slide 3 History of Nurse Navigator
Slide 1 The Nurse Navigators role in Early Stage Breast Cancer, and Development of Tailored Treatment Plan Laura Ochoa, RN, ANP-BC, Ph.D. Slide 2 Barnes Jewish Hospital at Washington University Slide 3
More informationAccelerated partial breast irradiation (APBI) has been in
ORIGINAL ARTICLE Six-Year Results From a Phase I/II Trial for Hypofractionated Accelerated Partial Breast Irradiation Using a 2-Day Dose Schedule John B. Wilkinson, MD,* Peter Y. Chen, MD,w Michelle F.
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Medical Center Philadelphia, PA Professor (Adjunct)
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 27 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationAccelerated Partial Breast Irradiation FACTS & MYTHS
Accelerated Partial Breast Irradiation (APBI) Accelerated Partial Breast Irradiation FACTS & MYTHS V.Strnad Radiation options after breast conserving surgery Whole Breast Irradiation (EBRT) APBI technique
More informationPavel ŠLAMPA, Jana RUZICKOVA, Barbora ONDROVA, Hana TICHA, Hana DOLEZELOVA
Sole conformal perioperative interstitial brachytherapy of early stage breast carcinoma using high-dose rate afterloading: longer-term results and toxicity Received: 0.09.2007 Accepted: 7.02.2008 Subject:
More informationBreast Brachytherapy: How to Allay Fears of Patients and Colleagues, and What Are Our Expectations for the Future?
Breast Brachytherapy: How to Allay Fears of Patients and Colleagues, and What Are Our Expectations for the Future? Vratislav Strnad, MD, PhD, Prof. Department of Radiation Therapy University Hospital Erlangen
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationSSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Dr. Yvonne Tsang St. Paul s Hospital Introductions Breast-conserving
More informationRecent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective
Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Tokyo-West Tokushukai Hospital Department of Breast Oncology Tokyo-West Tokushukai Hospital, Tokyo, Japan Kaz Sato, MD,
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES. Page: 1 of 10
Page: 1 of 10 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title BRACHYTHERAPY AFTER BREAST-CONSERVING SURGERY, AS BOOST WITH WHOLE BREAST IRRADIATION OR ALONE AS ACCELERATED PARTIAL BREAST IRRADIATION
More informationAccelerated Partial Breast Irradiation: A Review and Description of an Early North American Surgical Experience With the Intrabeam Delivery System
A variety of techniques for accelerated partial breast irradiation are available. Photo courtesy of Lisa Scholder. Hidden Power, 24ʺ 28ʺ. Accelerated Partial Breast Irradiation: A Review and Description
More informationMEDICAL POLICY. POLICY NUMBER: CATEGORY: Technology Assessment. Proprietary Information of Excellus Health Plan, Inc.
MEDICAL POLICY SUBJECT: BRACHYTHERAPY AFTER BREAST- WHOLE BREAST OR ALONE PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationBenefit of Adjuvant Brachytherapy Versus External Beam Radiation for Early Breast Cancer: Impact of Patient Stratification on Breast Preservation
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Breast Cancer Benefit of Adjuvant Brachytherapy Versus External Beam Radiation for Early Breast Cancer:
More informationWhy Choose Brachytherapy and Not External Beam RT or IORT?
May 30 31, 2014 Miami Beach, FL USA Why Choose Brachytherapy and Not External Beam RT or IORT? Csaba Polgár, MD, PhD, MSc National Institute of Oncology Budapest, Hungary 1 Disclosure Csaba Polgár, MD,
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationClassifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology
2059 Classifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology New Primary Tumors Have More Favorable Outcomes than True Local Disease Recurrences Eugene Huang,
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationSan Antonio Breast Cancer Symposium 2009: Highlights in Radiation Oncology. Outline
San Antonio Breast Cancer Symposium 2009: Highlights in Radiation Oncology Catherine Park, M.D. UCSF Radiation Oncology Outline IMRT Trial: Abstract#: 71 APBI for DCIS and IBC Background: ECOG 5194 Abstracts
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationPartial Breast Irradiation using adaptive MRgRT
Partial Breast Irradiation using adaptive MRgRT Shyama Tetar, radiation-oncologist VUmc Amsterdam 15-12-2017 5 th Vumc SBRT symposium 2017 Current practice Breast conserving treatment (BCT) Breast conserving
More informationWhat is an Adequate Lumpectomy Margin in 2018?
What is an Adequate Lumpectomy Margin in 2018? Stuart J. Schnitt, M.D. Brigham and Women s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School Boston, MA None Disclosures Topics Current
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationBrachytherapy is better than external beam therapy for partial breast irradiation
Brachytherapy is better than external beam therapy for partial breast irradiation For the proposition: Dorin Todor Virginia Commonwealth University, Richmond, VA AAPM 55 th Annual Meeting, Indianapolis,
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationCancer. Savita Dandapani
New Modalities for Breast Cancer Savita Dandapani Disclosures Accuray Talk at ASTRO 10/2015. Xoft provided slides for the partial breast radiation equipment. Early Stage: Deep Inspiratory Breath Hold (DIBH)
More informationPRACTICE GUIDELINE FOR BREAST CONSERVATION THERAPY IN THE MANAGEMENT OF INVASIVE BREAST CARCINOMA
The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationVersion STUDY PROTOCOL IRMA
Version 30.07.2008 STUDY PROTOCOL IRMA BREAST CANCER WITH LOW RISK OF LOCAL RECURRENCE: PARTIAL AND ACCELERATED RADIATION WITH THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY (3DCRT) VS. STANDARD RADIOTHERAPY
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationMETASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER
Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationApplicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery
Ann Surg Oncol (2015) 22:1128 1132 DOI 10.1245/s10434-014-4090-y ORIGINAL ARTICLE BREAST ONCOLOGY Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing
More informationOral cavity cancer Post-operative treatment
Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection
More informationRepeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates
Ann Surg Oncol (2012) 19:3771 3776 DOI 10.1245/s10434-012-2404-5 ORIGINAL ARTICLE BREAST ONCOLOGY Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the
More informationSpeaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationBy Rufus Mark, MD, Gail Lebovic, MD, Valerie Gorman, MD, Oscar Calvo, PhD. TABLE 1 EARLY STAGE BREAST CANCER RANDOMIZED TRIALS M vs.
EVOLUTION OF BREAST CONSERVATION RADIATION TREATMENT TECHNIQUES IN BREAST CANCER : FROM 6 WEEKS TO 3 WEEKS TO 1 WEEK TO 1 DAY AND FROM WHOLE BREAST TO PARTIAL BREAST By Rufus Mark, MD, Gail Lebovic, MD,
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationInterstitial Brachytherapy (IBT) as a Boost For Breast Cancer in Women With Augmentation Implants
Do et al. Page 1 Interstitial Brachytherapy (IBT) as a Boost For Breast Cancer in Women With Augmentation Implants Do, Ly MD 1, Syed, Nisar MD 2, Puthawala, Ajmel MD 2, Dowlatshahi, Morteza MD 1 Su Catherine
More informationAccelerated Partial-Breast Irradiation: Outcomes and Future Perspectives
Accelerated Partial-Breast Irradiation: Outcomes and Future Perspectives Chirag Shah, MD, Vivek Verma, MD, Michael A. Weller, MD, Eric Westerbeck, BS, Kyle Reilly, BS, and Frank Vicini, MD, FACR Abstract
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP120 Section: Medical Benefit Policy Subject: Intracavitary Balloon Brachytherapy for Breast Cancer I. Policy: Intracavitary Balloon Brachytherapy for Breast Cancer
More informationSupplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
More informationIntraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience
IORT for breast cancer Intraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience Roberto Orecchia 1,2, Maria Cristina Leonardi 1, Patrick
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationCOMMENTARY. Workshop on Partial Breast Irradiation: State of the Art and the Science, Bethesda, MD, December 8 10, 2002
COMMENTARY Workshop on Partial Breast Irradiation: State of the Art and the Science, Bethesda, MD, December 8 10, 2002 P. Wallner, D. Arthur, H. Bartelink, J. Connolly, G. Edmundson, A. Giuliano, N. Goldstein,
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationChapter 9 Radiotherapy A New Approach to Risk- Adapted Selective Radiotherapy
Chapter 9 Radiotherapy A New Approach to Risk- Adapted Selective Radiotherapy Csaba Polgár 9.1 Introduction During the last forty years, breast-conserving surgery (BCS) followed by whole breast irradiation
More information